New diabetes combo pill shows promise in Late-Stage trial

NCT ID NCT05814393

Completed Disease control Sponsor: JW Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial tested whether adding an experimental drug called JW0201 to standard diabetes medications (metformin and empagliflozin) helps lower blood sugar more effectively. The study involved 200 adults with type 2 diabetes whose blood sugar was not well controlled on their current treatment. Participants took either JW0201 or a placebo for 24 weeks, and researchers measured changes in HbA1c, a key blood sugar marker.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JW0201 (an experimental drug added to metformin and empagliflozin)
What this could lead to: If successful, JW0201 could offer a new add-on option to help people with type 2 diabetes achieve better blood sugar control when standard medications are not enough.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The drug may not prove significantly better than placebo, and side effects are possible. It is not a cure and requires ongoing medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Kangbuk Samsung Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.